Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Humongous Health-Care Stocks This Week: Pharmacyclics, Inc. (PCYC) and More

Sweet! No, I’m not talking about leftover Valentine’s Day candy and chocolates. Sweet is the operative word for the returns attained by several health-care stocks this week. Here are three of the week’s most humongous performers.

Help from Uncle Sugar
Shares in small biotech Pharmacyclics, Inc. (NASDAQ:PCYC) jumped 24% this week with a little help from “Uncle Sugar.” The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to ibrutinib for treating relapsed or refractory mantle cell lymphoma and Waldenstrom’s macroglobulinemia.

Pharmacyclics, Inc. (NASDAQ:PCYC)Pharmacyclics also reported quarterly results after the market closed on Thursday. Those numbers beat analyst expectations, but they weren’t nearly as important as the good news from the FDA.

The Breakthrough Therapy Designation also presents good news for Johnson & Johnson (NYSE:JNJ), whose Janssen unit has partnered with Pharmacyclics on ibrutinib. This designation, which was first enacted last year, allows for a faster development and review process. Pharmacyclics and Janssen are in discussions with the FDA to determine exactly what impact it will have for the drug.

Like a box of chocolates
The great fictional philosopher Forrest Gump passed on this bit of wisdom from his mother: “Life is a like a box of chocolates. You never know what you’re going to get.” ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares shot up 13% this week on news that the company will soon get to open its version of a box of chocolates.

Ziopharm announced on Tuesday that enough progression-free survival events have been reached to wrap up data collection and begin analysis from a phase 3 study of palifosfamide. This late-stage trial is testing use of the drug in treating patients with soft tissue sarcoma. The company expects to announce results from the study at the end of March.

Another phase 3 study is also under way for studying the effect of palifosfamide  in combination with carboplatin and etoposide in treating small cell lung cancer. Even if Ziopharm isn’t happy with the results to be announced in March, another “piece of chocolate” awaits.

Short and sweet
There’s no love lost between Carl Icahn and Bill Ackman. The highly publicized skirmish between the two billionaire investors took another twist this week. Shares of Herbalife Ltd. (NYSE:HLF) rose 8% this week after Icahn’s 13% stake in the company was reported.At one point on Friday, the stock was up 25% for the week. Those gains didn’t hold, though.

It looks like Carl Icahn is attempting to fulfill his own prophecy made on CNBC a few weeks ago when he stated that Herbalife “could be the mother of all short squeezes.” The regulatory filing made public on Thursday revealed that Icahn bought 2.5 million shares and call options for another 11.5 million shares in Herbalife over the last several weeks. That’s a big bet.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.